Lipocine vs Vistagen Therapeutics
LPCN and VTGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LPCN and VTGN compare
Lipocine is the larger company, worth 1.8 times as much as Vistagen Therapeutics ($14.1M against $8.0M).
Lipocine keeps more of each dollar of sales as profit, with a net margin of −249% compared with −2475% at Vistagen Therapeutics.
Lipocine scores higher on the StockData Score (11 against 9 for Vistagen Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LPCN | VTGN |
|---|---|---|
| Size and price | ||
| Market cap | $14.1M | $8.0M |
| Share price | $1.71 | $0.180 |
| Change, 1 year | −41.4% | −95.6% |
| Change, 5 years | −91.4% | −99.7% |
| Beta (5Y) | 0.66 | 1.31 |
| Employees | 14 | 41 |
| StockData Score | ||
| Total score | 11 (better) | 9 |
| Valuation score | 3 | 3 |
| Growth score | 1 (better) | 0 |
| Performance score | 2 (better) | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.8× | 3.4× (better) |
| P/B | 0.7× | 0.5× (better) |
| Fair value | $3.29 | $0.660 |
| Margin of safety | 48.0% | 72.7% (better) |
| Growth | ||
| Revenue growth (TTM) | −13.4% | – |
| Revenue growth, 5Y average | – | 3.1% |
| Profitability | ||
| Operating margin | −269% (better) | −2542% |
| Net margin | −249% (better) | −2475% |
| Return on equity | −52.9% (better) | −145% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 11.36 (better) | 2.64 |
| Altman Z-score | −9.08 (better) | −37.10 |
| Piotroski F-score | 1 | 2 (better) |
| Dividends and buybacks | ||
| Buyback yield | −114% | – |
| Shareholder yield | −114% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 36.2% | 26.5% |
| Held by insiders | 8.4% | 0.52% |
| Insider net buying, 12 months | $517K | – |
| Short interest, % of float | 4.3% | 5.6% |
Go deeper
- LPCN stock overview
- LPCN income statement
- LPCN valuation and score
- VTGN stock overview
- VTGN income statement
- VTGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.